Navaneethan Radhakrishnan
Overview
Explore the profile of Navaneethan Radhakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Radhakrishnan N, Kaul S, Wadhwa R, Yang L, Sundar D
Int J Mol Sci
. 2025 Jan;
26(2).
PMID: 39859387
Understanding the permeation of drugs through the intercellular lipid matrix of the stratum corneum layer of skin is crucial for effective transdermal delivery. Molecular dynamics simulations can provide molecular insights...
2.
Tsai C, Lu Y, Chan Y, Radhakrishnan N, Chang Y, Lin S, et al.
Comput Struct Biotechnol J
. 2023 Dec;
21:5698-5711.
PMID: 38074473
Variants in the gap junction beta-2 () gene are the most common cause of hereditary hearing impairment. However, how variants lead to local physicochemical and structural changes in the hexameric...
3.
Malik V, Radhakrishnan N, Kaul S, Wadhwa R, Sundar D
Biomolecules
. 2022 Feb;
12(2).
PMID: 35204712
Withaferin-A (Wi-A), a secondary metabolite extracted from Ashwagandha (), has been shown to possess anticancer activity. However, the molecular mechanism of its action and the signaling pathways have not yet...
4.
Radhakrishnan N, Dhanjal J, Sari A, Ishida Y, Terao K, Kaul S, et al.
Discov Oncol
. 2022 Feb;
12(1):64.
PMID: 35201513
Mutations in the tumor suppressor protein p53 is a prevalent feature in majority of cancers resulting in inactivation of its activities related to control of cell cycle progression and proliferation....
5.
Radhakrishnan N, Kaul S, Wadhwa R, Sundar D
Membranes (Basel)
. 2022 Jan;
12(1).
PMID: 35054590
Development of drugs that are selectively toxic to cancer cells and safe to normal cells is crucial in cancer treatment. Evaluation of membrane permeability is a key metric for successful...
6.
Dhanjal J, Vora D, Radhakrishnan N, Sundar D
Methods Mol Biol
. 2021 Oct;
2349:147-166.
PMID: 34718995
The easily programmable CRISPR/Cas9 system has found applications in biomedical research as well as microbial and crop applications, due to its ability to create site-specific edits. This powerful and flexible...
7.
Sari A, Bhargava P, Dhanjal J, Putri J, Radhakrishnan N, Shefrin S, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32380701
We have earlier reported anticancer activity in Withaferin A (Wi-A), a withanolide derived from Ashwagandha () and caffeic acid phenethyl ester (CAPE), an active compound from New Zealand honeybee propolis....
8.
Garg S, Afzal S, Elwakeel A, Sharma D, Radhakrishnan N, Dhanjal J, et al.
Mar Drugs
. 2019 Jun;
17(6).
PMID: 31195739
Fucoxanthin is commonly found in marine organisms; however, to date, it has been one of the scarcely explored natural compounds. We investigated its activities in human cancer cell culture-based viability,...
9.
CRISPcut: A novel tool for designing optimal sgRNAs for CRISPR/Cas9 based experiments in human cells
Dhanjal J, Radhakrishnan N, Sundar D
Genomics
. 2018 Apr;
111(4):560-566.
PMID: 29605634
The ability to direct the CRISPR/Cas9 nuclease to a unique target site within a genome would have broad use in targeted genome engineering. However, CRISPR RNA is reported to bind...
10.
Malik V, Dhanjal J, Kumari A, Radhakrishnan N, Singh K, Sundar D
Methods
. 2017 Aug;
131:10-21.
PMID: 28843611
Drug discovery in simple words is all about finding small molecular compounds that possess the potential to interact with specific bio-macromolecules, mainly proteins, thereby bringing a desired effect in the...